[LCID Study Number: 20193055]
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis
This study is being done to find out if starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (time being alive) for patients with your type of cancer.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3071